ROHM Co., Ltd. (TYO:6963)

Theseus Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	446,395	448,466	467,780	507,882	452,124	359,888
Revenue Growth (YoY)	-4.18%	-4.13%	-7.90%	12.33%	25.63%	-0.83%
Cost of Revenue	375,958	374,203	322,088	314,220	289,803	242,252
Gross Profit	70,437	74,263	145,692	193,662	162,321	117,636
Selling, General & Admin	54,328	57,079	57,942	58,784	54,715	47,609
Research & Development	57,245	57,245	44,423	42,560	36,126	31,537
Operating Expenses	111,573	114,324	102,365	101,344	90,841	79,146
Operating Income	-41,136	-40,061	43,327	92,318	71,480	38,490
Interest Expense	-1,079	-1,040	-436	-133	-114	-95
Interest & Investment Income	9,177	10,090	6,903	4,459	2,022	2,399
Currency Exchange Gain (Loss)	-2,833	226	12,407	11,387	8,090	-1,062
Other Non Operating Income (Expenses)	-591	1,086	6,999	1,498	1,073	938
EBT Excluding Unusual Items	-36,462	-29,699	69,200	109,529	82,551	40,670
Gain (Loss) on Sale of Investments	6,229	6,044	-246	-622	2,190	1,392
Gain (Loss) on Sale of Assets	399	382	4,105	1,311	583	-120
Asset Writedown	-38,030	-38,007	-11,236	-711	-1,137	-1,089
Other Unusual Items	4,548	4,548	9,859	-1	-329	-342
Pretax Income	-63,316	-56,732	71,682	109,506	83,858	40,511
Income Tax Expense	-12,771	-6,691	17,675	29,104	17,001	3,478
Earnings From Continuing Operations	-50,545	-50,041	54,007	80,402	66,857	37,033
Minority Interest in Earnings	-17	-24	-42	-27	-30	-31
Net Income	-50,562	-50,065	53,965	80,375	66,827	37,002
Preferred Dividends & Other Adjustments	25	25	2	31	33	33
Net Income to Common	-50,587	-50,090	53,963	80,344	66,794	36,969
Net Income Growth	-	-	-32.86%	20.27%	80.60%	44.35%
Shares Outstanding (Basic)	386	386	389	393	393	393
Shares Outstanding (Diluted)	386	386	401	404	404	405
Shares Change (YoY)	0.01%	-3.66%	-0.93%	0.01%	-0.12%	-3.01%
EPS (Basic)	-131.06	-129.78	138.81	204.66	170.15	94.06
EPS (Diluted)	-131.06	-129.78	134.35	198.35	164.86	90.99
EPS Growth	-	-	-32.27%	20.31%	81.19%	48.61%
Free Cash Flow	-59,697	-51,836	-83,415	-2,141	25,602	13,598
Free Cash Flow Per Share	-154.66	-134.30	-208.21	-5.29	63.32	33.59
Dividend Per Share	50.000	50.000	50.000	50.000	46.250	37.500
Dividend Growth	-	-	-	8.11%	23.33%	-
Gross Margin	-	16.56%	31.14%	38.13%	35.90%	32.69%
Operating Margin	-9.21%	-8.93%	9.26%	18.18%	15.81%	10.70%
Profit Margin	-11.33%	-11.17%	11.54%	15.82%	14.77%	10.27%
Free Cash Flow Margin	-13.37%	-11.56%	-17.83%	-0.42%	5.66%	3.78%
EBITDA	35,655	43,357	115,396	148,458	113,507	78,657
EBITDA Margin	-	9.67%	24.67%	29.23%	25.11%	21.86%
D&A For EBITDA	76,791	83,418	72,069	56,140	42,027	40,167
EBIT	-41,136	-40,061	43,327	92,318	71,480	38,490
EBIT Margin	-	-8.93%	9.26%	18.18%	15.81%	10.70%
Effective Tax Rate	-	-	24.66%	26.58%	20.27%	8.58%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.